Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (16782)	5/14/2005 6:03:17 PM
From: zeta1961	Read Replies (1) \| Respond to of 52153

The study randomized 569 patients to receive either gemcitabine plus concurrent Tarceva or gemcitabine plus placebo. This is where I get so angry..they are using their marketing muscle to prostitute these marginally effective drugs(especially pains me when I see it in these orphan diseases) while smaller companies with much more promising molecules/modalities have trouble accruing or getting funded.. And it's not just the doc's..nurses are hugely culpable..they are gatekeepers..just had their onc meeting right before ASCO..EVERY 'educational' session was paid for by the DNA's, MRK's. End of rant! Zeta